Globenewswire·2025-11-24 13:30Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding letter of intent with a South Korean pharmaceutical company to explore the potential in-licensing and development of its plant-derived new drug MCS-2 for the Korean market [1][2] Group 1: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][4] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - Jyong Biotech is advancing several botanical drug candidates, including its primary candidate BOTRESO® and other clinical and preclinical-stage candidates [4] Group 2: Strategic Partnership - The engagement with the South Korean pharmaceutical company aligns with Jyong Biotech's co-commercialization strategy, aiming to leverage the partner's established sales networks and local regulatory expertise [2] - The partnership, if finalized, is expected to enhance market access and patient reach in Korea by utilizing the partner's commercial infrastructure [2][3] - The letter of intent is non-exclusive and subject to due diligence, regulatory review, and negotiation of definitive agreements [2] Group 3: Product Development Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [3] - The company is committed to complying with regulatory disclosure obligations and will provide updates on material developments as they occur [3]